New hope for rare leukemia: trial tests powerful drug combo
NCT ID NCT06991920
Summary
This study is testing a new combination treatment for adults with a rare and aggressive type of leukemia that is difficult to classify and treat. The treatment combines a targeted immunotherapy drug (blinatumomab), a standard chemotherapy approach, and two other newer drugs (venetoclax and TKI drugs). The goal is to see if this combination is safe and more effective at controlling the disease and helping patients live longer than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.